{"id":62022,"date":"2025-10-14T22:03:48","date_gmt":"2025-10-14T20:03:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/insitro-extends-research-collaboration-with-bristol-myers-squibb-leveraging-insitros-chemml-discovery-platform\/"},"modified":"2025-10-14T22:03:48","modified_gmt":"2025-10-14T20:03:48","slug":"insitro-extends-research-collaboration-with-bristol-myers-squibb-leveraging-insitros-chemml-discovery-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/insitro-extends-research-collaboration-with-bristol-myers-squibb-leveraging-insitros-chemml-discovery-platform\/","title":{"rendered":"insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro\u2019s ChemML Discovery Platform"},"content":{"rendered":"
\n

\nNovel ALS target identified preclinically; next phase of collaboration will leverage insitro\u2019s ChemML\u2122 platform to discover molecules with potential as next-generation therapies for ALS<\/i><\/p>\n

\ninsitro’s ChemML\u2122 platform integrates proprietary binding and ADMET data at scale with best-in-class machine learning and compute infrastructure to discover and optimize new small molecule therapeutics<\/i><\/p>\n

\nCollaboration extension builds on 5-year agreement announced in 2020<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, a pioneer in machine learning\u2013driven drug discovery and development, and Bristol Myers Squibb (NYSE: BMY), today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe collaboration extension will leverage insitro\u2019s AI-enabled ChemML\u2122 platform to design new medicines for a novel ALS target that was identified in the first biological evaluation phase and may provide up to $20 million in new funding for the one-year extension. The successful delivery of a new therapeutic from the collaboration could have an aggregate value of more than $2 billion in discovery, development, regulatory and commercial milestone payments to insitro in addition to royalty payments.<\/p>\n

\n\u201cOur collaboration with Bristol Myers Squibb has uncovered novel targets with potential to address the underlying biology of ALS,\u201d said Daphne Koller, Ph.D., founder and CEO of insitro. \u201cWe are now moving into the next phase \u2013 turning these discoveries into medicines. With ChemML, our end-to-end drug design platform, we can translate novel targets into advanced small-molecule leads rapidly, leveraging a differentiated set of capabilities that spans AI-driven modeling, medicinal chemistry, and structural biology. While advancing these initial drug candidates, we will continue our efforts to identify additional new targets that have the potential to be disease-modifying. Our aim remains unwavering: to deliver truly transformative treatments that enable people with ALS to live longer.\u201d<\/p>\n

\nLeveraging insitro\u2019s ChemML\u2122 platform to discover and advance novel ALS medicines<\/b><\/p>\n

\ninsitro’s proprietary ChemML\u2122 <\/b>platform enables end-to-end small molecule discovery and optimization built through internal development and the acquisition of Haystack Sciences. Although significant efforts have been made to apply AI\/ML to various aspects of drug discovery, advancing novel therapeutics for complex and challenging targets remains a slow and costly iterative process. ChemML\u2122 <\/b>seamlessly integrates multiple in silico<\/i> and laboratory capabilities to rapidly design and optimize new small molecule therapies across different disease areas. These include:<\/p>\n